EUROFINS SCIENTIFIC (ERF.PA) Stock Fundamental Analysis

EPA:ERF • FR0014000MR3

68.16 EUR
+0.44 (+0.65%)
Last: Feb 27, 2026, 07:00 PM
Fundamental Rating

5

Taking everything into account, ERF scores 5 out of 10 in our fundamental rating. ERF was compared to 18 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ERF get a neutral evaluation. Nothing too spectacular is happening here. ERF has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • ERF had positive earnings in the past year.
  • In the past year ERF had a positive cash flow from operations.
  • ERF had positive earnings in each of the past 5 years.
  • Each year in the past 5 years ERF had a positive operating cash flow.
ERF.PA Yearly Net Income VS EBIT VS OCF VS FCFERF.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

1.2 Ratios

  • The Return On Assets of ERF (6.29%) is better than 61.11% of its industry peers.
  • Looking at the Return On Equity, with a value of 15.21%, ERF is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
  • With a decent Return On Invested Capital value of 11.61%, ERF is doing good in the industry, outperforming 77.78% of the companies in the same industry.
Industry RankSector Rank
ROA 6.29%
ROE 15.21%
ROIC 11.61%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ERF.PA Yearly ROA, ROE, ROICERF.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • Looking at the Profit Margin, with a value of 6.48%, ERF is doing worse than 61.11% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ERF has declined.
  • ERF's Operating Margin of 12.42% is on the low side compared to the rest of the industry. ERF is outperformed by 72.22% of its industry peers.
  • ERF's Operating Margin has declined in the last couple of years.
  • ERF has a Gross Margin of 22.25%. This is amonst the worse of the industry: ERF underperforms 83.33% of its industry peers.
  • ERF's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 12.42%
PM (TTM) 6.48%
GM 22.25%
OM growth 3Y-11.06%
OM growth 5Y-10.4%
PM growth 3Y-9.05%
PM growth 5Y-6.87%
GM growth 3Y-1.72%
GM growth 5Y-3.8%
ERF.PA Yearly Profit, Operating, Gross MarginsERF.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ERF is still creating some value.
  • ERF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ERF.PA Yearly Shares OutstandingERF.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ERF.PA Yearly Total Debt VS Total AssetsERF.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • ERF has an Altman-Z score of 3.06. This indicates that ERF is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ERF (3.06) is better than 61.11% of its industry peers.
  • The Debt to FCF ratio of ERF is 5.14, which is a neutral value as it means it would take ERF, 5.14 years of fcf income to pay off all of its debts.
  • ERF has a better Debt to FCF ratio (5.14) than 72.22% of its industry peers.
  • ERF has a Debt/Equity ratio of 0.82. This is a neutral value indicating ERF is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.82, ERF is not doing good in the industry: 61.11% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF 5.14
Altman-Z 3.06
ROIC/WACC1.32
WACC8.77%
ERF.PA Yearly LT Debt VS Equity VS FCFERF.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.3 Liquidity

  • ERF has a Current Ratio of 1.09. This is a normal value and indicates that ERF is financially healthy and should not expect problems in meeting its short term obligations.
  • ERF has a Current ratio (1.09) which is comparable to the rest of the industry.
  • ERF has a Quick Ratio of 1.03. This is a normal value and indicates that ERF is financially healthy and should not expect problems in meeting its short term obligations.
  • ERF has a Quick ratio (1.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.03
ERF.PA Yearly Current Assets VS Current LiabilitesERF.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

5

3. Growth

3.1 Past

  • ERF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.73%, which is quite good.
  • Measured over the past years, ERF shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.23% on average per year.
  • Looking at the last year, ERF shows a very strong growth in Revenue. The Revenue has grown by 53.32%.
  • ERF shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.05% yearly.
EPS 1Y (TTM)12.73%
EPS 3Y-4.43%
EPS 5Y-0.23%
EPS Q2Q%6.78%
Revenue 1Y (TTM)53.32%
Revenue growth 3Y2.82%
Revenue growth 5Y6.05%
Sales Q2Q%4.3%

3.2 Future

  • ERF is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.24% yearly.
  • ERF is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.98% yearly.
EPS Next Y10.84%
EPS Next 2Y12.5%
EPS Next 3Y15.73%
EPS Next 5Y15.24%
Revenue Next Year4.81%
Revenue Next 2Y5.71%
Revenue Next 3Y6.11%
Revenue Next 5Y6.98%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ERF.PA Yearly Revenue VS EstimatesERF.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2B 4B 6B 8B
ERF.PA Yearly EPS VS EstimatesERF.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6

5

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 18.32 indicates a rather expensive valuation of ERF.
  • Based on the Price/Earnings ratio, ERF is valued a bit cheaper than the industry average as 72.22% of the companies are valued more expensively.
  • ERF's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.10.
  • Based on the Price/Forward Earnings ratio of 16.87, the valuation of ERF can be described as correct.
  • 72.22% of the companies in the same industry are more expensive than ERF, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, ERF is valued a bit cheaper.
Industry RankSector Rank
PE 18.32
Fwd PE 16.87
ERF.PA Price Earnings VS Forward Price EarningsERF.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ERF is valued cheaper than 83.33% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ERF indicates a rather cheap valuation: ERF is cheaper than 88.89% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 14.39
EV/EBITDA 8.18
ERF.PA Per share dataERF.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • ERF's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • ERF's earnings are expected to grow with 15.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.69
PEG (5Y)N/A
EPS Next 2Y12.5%
EPS Next 3Y15.73%

5

5. Dividend

5.1 Amount

  • ERF has a Yearly Dividend Yield of 1.06%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 0.44, ERF pays a better dividend. On top of this ERF pays more dividend than 83.33% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.80, ERF's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 1.06%

5.2 History

  • On average, the dividend of ERF grows each year by 16.51%, which is quite nice.
Dividend Growth(5Y)16.51%
Div Incr Years1
Div Non Decr Years1
ERF.PA Yearly Dividends per shareERF.PA Yearly Dividends per shareYearly Dividends per share 2018 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

  • ERF pays out 15.92% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of ERF is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP15.92%
EPS Next 2Y12.5%
EPS Next 3Y15.73%
ERF.PA Yearly Income VS Free CF VS DividendERF.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
ERF.PA Dividend Payout.ERF.PA Dividend Payout, showing the Payout Ratio.ERF.PA Dividend Payout.PayoutRetained Earnings

EUROFINS SCIENTIFIC

EPA:ERF (2/27/2026, 7:00:00 PM)

68.16

+0.44 (+0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)01-29
Earnings (Next)04-22
Inst Owners35.61%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap12.42B
Revenue(TTM)10.66B
Net Income(TTM)691.00M
Analysts67
Price Target72.41 (6.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.06%
Yearly Dividend0.52
Dividend Growth(5Y)16.51%
DP15.92%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.01%
PT rev (3m)6.51%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.87%
Revenue NY rev (3m)-0.87%
Valuation
Industry RankSector Rank
PE 18.32
Fwd PE 16.87
P/S 1.17
P/FCF 14.39
P/OCF 8.87
P/B 2.73
P/tB N/A
EV/EBITDA 8.18
EPS(TTM)3.72
EY5.46%
EPS(NY)4.04
Fwd EY5.93%
FCF(TTM)4.74
FCFY6.95%
OCF(TTM)7.69
OCFY11.28%
SpS58.51
BVpS24.95
TBVpS-4.41
PEG (NY)1.69
PEG (5Y)N/A
Graham Number45.69
Profitability
Industry RankSector Rank
ROA 6.29%
ROE 15.21%
ROCE 15.48%
ROIC 11.61%
ROICexc 12.8%
ROICexgc 41.1%
OM 12.42%
PM (TTM) 6.48%
GM 22.25%
FCFM 8.1%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-11.06%
OM growth 5Y-10.4%
PM growth 3Y-9.05%
PM growth 5Y-6.87%
GM growth 3Y-1.72%
GM growth 5Y-3.8%
F-Score6
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF 5.14
Debt/EBITDA 1.9
Cap/Depr 85.24%
Cap/Sales 5.04%
Interest Coverage 11.51
Cash Conversion 71.65%
Profit Quality 124.89%
Current Ratio 1.09
Quick Ratio 1.03
Altman-Z 3.06
F-Score6
WACC8.77%
ROIC/WACC1.32
Cap/Depr(3y)81.48%
Cap/Depr(5y)89.24%
Cap/Sales(3y)7.8%
Cap/Sales(5y)8.16%
Profit Quality(3y)196.03%
Profit Quality(5y)160.87%
High Growth Momentum
Growth
EPS 1Y (TTM)12.73%
EPS 3Y-4.43%
EPS 5Y-0.23%
EPS Q2Q%6.78%
EPS Next Y10.84%
EPS Next 2Y12.5%
EPS Next 3Y15.73%
EPS Next 5Y15.24%
Revenue 1Y (TTM)53.32%
Revenue growth 3Y2.82%
Revenue growth 5Y6.05%
Sales Q2Q%4.3%
Revenue Next Year4.81%
Revenue Next 2Y5.71%
Revenue Next 3Y6.11%
Revenue Next 5Y6.98%
EBIT growth 1Y27.19%
EBIT growth 3Y-8.55%
EBIT growth 5Y-4.98%
EBIT Next Year83.08%
EBIT Next 3Y29.99%
EBIT Next 5Y24.68%
FCF growth 1Y9.17%
FCF growth 3Y21.94%
FCF growth 5Y-0.12%
OCF growth 1Y6.15%
OCF growth 3Y7.21%
OCF growth 5Y2.73%

EUROFINS SCIENTIFIC / ERF.PA FAQ

What is the ChartMill fundamental rating of EUROFINS SCIENTIFIC (ERF.PA) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ERF.PA.


What is the valuation status for ERF stock?

ChartMill assigns a valuation rating of 5 / 10 to EUROFINS SCIENTIFIC (ERF.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for EUROFINS SCIENTIFIC?

EUROFINS SCIENTIFIC (ERF.PA) has a profitability rating of 4 / 10.


What is the earnings growth outlook for EUROFINS SCIENTIFIC?

The Earnings per Share (EPS) of EUROFINS SCIENTIFIC (ERF.PA) is expected to grow by 10.84% in the next year.


Can you provide the dividend sustainability for ERF stock?

The dividend rating of EUROFINS SCIENTIFIC (ERF.PA) is 5 / 10 and the dividend payout ratio is 15.92%.